Members

Blog Posts

qumar

Posted by jack on September 19, 2024 at 8:01am 1 Comment

I think youve produced some genuinely interesting points. Not too many people would in fact think about this the way you just did. Im truly impressed that theres so substantially about this subject thats been uncovered and you did it so properly, with so a lot class. Good one you, man! Genuinely great stuff here. gcam lmc 8.4 r18

Scleroderma Diagnostics and Therapeutics Market Share, Overview, Competitive Analysis and Forecast 2031

Posted by Prajakta on September 19, 2024 at 8:01am 0 Comments

The Scleroderma Diagnostics and Therapeutics Market in 2023 is US$ 2.92 billion, and is expected to reach US$ 6.49 billion by 2031 at a CAGR of 10.50%.



FutureWise Research published a report that analyzes Scleroderma Diagnostics and Therapeutics Market trends to predict the market's growth. The report begins with a description of the business environment and… Continue

South Korea Botulinum Toxin Type A Market Size, Share And Growth Report, 2030

Posted by sara James on September 19, 2024 at 8:00am 0 Comments

The South Korea Botulinum Toxin Type A Market size is anticipated to reach USD 386.9 million by 2030 and expanding at a CAGR of 10.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising aesthetic consciousness among the South Korean population fuels the demand for the market. South Koreans place…

Continue

Benign Prostatic Hyperplasia Treatment Market worth $14.1 billion by 2026

According to the new market research report "Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA], End User (Hospitals) - Global Forecast to 2026", published by MarketsandMarkets™, the Global BPH Treatment Market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026.

The growth of this BPH Treatment Market is driven by the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198000374

Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.

Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment. Drug treatment is the largest and the fastest-growing segment in this market. This can primarily be attributed to the use of medications as the first line of treatment among men with mild to moderate symptoms of BPH.

Home healthcare is expected to hold the largest share of the benign prostatic hyperplasia treatment market, in 2021.

Based on the end user, the market is segmented into home healthcare and hospitals & clinics. In 2019, home healthcare accounted for the largest share of this market, as most patients are prescribed medications over surgery. Patients are also advised to continue taking medications for a few weeks post-surgery and may even require catheters for a few days. As a result, the emphasis in his market is skewed toward home healthcare over hospital care.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=198000374

North America commanded the largest share of the benign prostatic hyperplasia treatment market in 2021.

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.

Key Players of Market:

The major players operating in benign prostatic hyperplasia treatment market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Teleflex Incorporated (US), Olympus Corporation (Japan), GlaxoSmithKline PLC (UK), Eli Lilly (US), Pfizer, Inc. (US), Abbott (US), Asahi Kasei Corporation (Japan), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Allergan plc (Ireland), Alembic (India), IPG Photonics Corporation (US), Richard Wolf GmbH (Germany), Unilab, Inc. (Philippines), Pharex Health Corporation (Philippines), Biolitec AG (Austria), Urologix, LLC (US), Advin Health Care (India), Medifocus, Inc. (Canada), Asclepion Laser Technologies GmbH (Germany), Pnn Medical A/S (Denmark), Surgical Lasers Inc. (Canada). Quanta Systems (Italy), Allium Ltd. (Israel), Lumenis Ltd. (Israel), KARL STORZ SE & Co. KG (Germany), and SRS Medical (US).

Views: 3

Comment

You need to be a member of On Feet Nation to add comments!

Join On Feet Nation

© 2024   Created by PH the vintage.   Powered by

Badges  |  Report an Issue  |  Terms of Service